All In MedTech

Device Trial Radar · NCT07457216

Visual and Patient-Reported Outcomes After Bilateral Non-Diffractive EDOF IOL Implantation

Visual and Patient-Reported Outcomes Following Bilateral Implantation of Non-Diffractive Extended Depth-of-Focus Intraocular Lenses in Patients Undergoing Cataract Surgery

Last checked: Nov 20, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Jan 3, 2025

Primary completion

Jan 30, 2025

Study completion Jan 31, 2025

Sponsor

Lead sponsor
Benha UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 9, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates visual outcomes and patient-reported satisfaction following bilateral cataract surgery using a non-diffractive extended depth-of-focus (EDOF) intraocular lens (AcrySof IQ Vivity). The purpose of the study is to assess distance, intermediate, and near visual acuity, refractive accuracy, contrast sensitivity, spectacle independence, and the presence of photic phenomena after implantation. Thirty patients undergoing bilateral phacoemulsification will be enrolled. Participants will be evaluated at 1 and 3 months postoperatively.

Conditions

  • Extended Depth-of-Focus Intraocular Lens
  • Cataract
  • Visual Acuity

Interventions

  • AcrySof IQ Vivity EDOF Intraocular LensDevice

    The AcrySof IQ Vivity is a non-diffractive extended depth-of-focus intraocular lens designed to provide an extended range of clear vision for distance and intermediate tasks while maintaining high optical quality and reducing photic phenomena such as glare and halos. The lens is implanted in the capsular bag during standard phacoemulsification surgery. Target refraction is emmetropia, and postoperative care includes a 4-week taper of combined topical antibiotic-steroid drops. Outcomes measured include visual acuity at distance, intermediate, and near, patient satisfaction, spectacle independence, and contrast sensitivity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Binocular Uncorrected Distance Visual Acuity (UDVA)Time frame: 1 month and 3 months postoperatively
  2. Monocular Uncorrected Distance Visual Acuity (UDVA)Time frame: 1 month and 3 months postoperatively
  3. Binocular Uncorrected Intermediate Visual Acuity (UIVA at 66 cm)Time frame: 1 month and 3 months postoperatively

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Benha University

    Banhā, Benha, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.